Trial
NCT04398134
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Assembly Biosciences
Collaborators
—
Condition
Chronic Hepatitis B
Intervention
ABI-H2158
Why stopped
Study stopped due to a safety signal of drug-induced liver injury in subjects receiving 2158
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-15